drug · antibody
imsidolimab
pre_registrationupdated 3mo agoby $VNDA Vanda Pharmaceuticals Inc.🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 7 investigational indications.
targets
IL36 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying imsidolimab
- phase3Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
- phase3Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
- phase2A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
- phase2A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
- phase2A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
- phase2A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
- phase2A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
- phase2A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that